MorphoSys Corp - MOR Net earnings per one share for the last twelve months
MorphoSys AG (MOR) has seen YoY net income per share growth over the last 12 months reflect a market balance, with the value stabilizing at 108.00. The business leverages the HuCAL and Ylanthia antibody biotech ecosystems, creating strong partner lock-in through licensing. These German developments block tumor growth, confirming the company's scientific potential. Final-stage drug trials for myelofibrosis will provide MorphoSys AG (MOR) with premium pricing power in the global market.
MOR (MorphoSys Corp): analytical breakdowns and indicator data
- current price and projected stock value:
- issuer market value details:
- company book value details:
- debt and liquidity data:
- earnings and market multiples details:
MOR - Net Income|Expected Net Profit MorphoSys AG|MOR - Price to Earnings Ratio|Market Cap to Projected Earnings MorphoSys AG|MOR - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation MorphoSys Corp|MOR - Operating profit EBITDA|Net earnings per share (EPS TTM) MorphoSys|MOR - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year morphosys.com|MOR - Earnings per share growth in current year|Expected earnings per share growth for next year MorphoSys AG
- revenue and sales details:
Fundamental company valuation:MorphoSys Inc MOR
Net income per share growth serves as a key indicator of capital efficiency amid expensive borrowing costs. This metric measures the rolling annual rate of profit change, assessing the business's ability to scale revenue. By analyzing the EPS YoY TTM trend, an investor can identify the risk of multiple compression during excessive investment inflows. For MorphoSys AG (MOR), this figure reflects the monetization potential of myelofibrosis therapy. The acquisition by the Swiss behemoth should transform current yields into global market growth.
Competitor analysis
Earnings per share for the trailing year ONC (BeiGene)|Halozyme Inc. (HALO) - Earnings per share for the last twelve months|RevMed - Earnings per share for the trailing year|AAPG (Ascentage Pharma Group International) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology, Inc. CGON|Net earnings per share for the last 12 months URGN (urogen.com)|Earnings per share for the last twelve months BCAX (Bicara Therapeutics)|Net earnings per share (EPS TTM) PSNL (personalis.com)|Earnings per share for the trailing year ERAS|DCTH - Earnings per share for the last twelve months|Y-mAbs Therapeutics (YMAB) - Net earnings per share for the last 12 months|AURA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months CADL|Earnings per share for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ACTU (Actuate Therapeutics, Inc)|Net earnings per share for the last four quarters Citius Oncology|TuHURA Biosciences, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Protara TARA|fatetherapeutics.com - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aadi Bioscience|TCRX: Net earnings per share (EPS TTM)|CSBR - Net earnings per share for the last four quarters|XBIT (XBiotech) - Net earnings per share (EPS TTM)|CVM: Earnings per share for the trailing year|Net earnings per share (EPS TTM) OSTX|RADX (Radiopharm Theranostics Limited) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ARTV (Artiva Biotherapeutics, Inc.)|Earnings per share for the trailing year ANL|VERU: Net earnings per share for the last 12 months|TPST - Net earnings per share (EPS TTM)|XLO (xiliotx.com) - Net earnings per share for the last 12 months|Renovaro Biosciences - Earnings per share for the trailing year|Net earnings per share for the last 12 months MURA|Earnings per share for the last twelve months KAPA|Net earnings per share for the last 12 months OKUR (OnKure Therapeutics Inc)|Net earnings per share (EPS TTM) CytoMed (GDTC)|Earnings per share for the last twelve months curis.com CRIS|APLM (Apollomics, Inc.) - Earnings per one share for the last 12 months|Tharimmune Corporation - Net earnings per share (EPS TTM)|ADVB (advanbiomed.com) - Earnings per share for the last 12 months|Genprex, Inc (GNPX) - Earnings per share for the last twelve months|CLDI: Earnings per share for the last four quarters|SBFM (Sunshine Biopharma, Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months XBIO (Xenetic Biosciences)|Net earnings per share (EPS TTM) SLRX|Purple Biotech - Earnings per share for the last 12 months|American Oncology Network - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGNE|CKPT - Earnings per share for the last twelve months|Elevation Oncology (ELEV) - Net earnings per share for the last 12 months|ICAD: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Ikena Oncology Inc.|NTBL (Notable Labs Ltd) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Viracta Therapeutics (VIRX)|Earnings per share for the last twelve months NAYA Bio (NAYA)|AAPGV: Earnings per one share for the last 12 months
